Linked Life Data

12562452

Source:http://linkedlifedata.com/resource/pubmed/id/12562452

Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
3
pubmed:dateCreated
2003-2-3
pubmed:abstractText
Mesalazine (5-aminosalicylic acid, 5-ASA)-containing formulations represent a cornerstone in the treatment of inflammatory bowel diseases. Recently, a new formulation has been developed to provide selective and more homogeneous release of 5-ASA compared to traditional systems.
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:month
Feb
pubmed:issn
0269-2813
pubmed:author
pubmed:issnType
Print
pubmed:volume
17
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
395-402
pubmed:dateRevised
2004-11-17
pubmed:meshHeading
pubmed:year
2003
pubmed:articleTitle
Gastrointestinal transit and 5-ASA release from a new mesalazine extended-release formulation.
pubmed:affiliation
Department of Clinical Pharmacology, University of Vienna Medical School, Austria. martin.brunner@univie.ac.at
pubmed:publicationType
Journal Article, Clinical Trial, Clinical Trial, Phase I